Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of cancer. Co. manages its operations in two reportable segments: Oncology Innovation Platform, which is focused on the research and development of its proprietary drugs and; Commercial Platform, which focused on the sales and marketing of drugs and the market development of its proprietary drugs. Co. is also continuing certain studies of oral paclitaxel and encequidar, the active product candidate using its Orascovery technology, based on a P-glycoprotein pump inhibitor. The ATNX average annual return since 2017 is shown above.
The Average Annual Return on the ATNX average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ATNX average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ATNX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|